Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial
S Dupuis-Girod, A Ambrun, E Decullier, AE Fargeton… - Jama, 2016 - jamanetwork.com
Background Epistaxis is the most frequent and disabling manifestation of hereditary
hemorrhagic telangiectasia (HHT). The efficacy of intravenous bevacizumab (an anti–
vascular endothelial growth factor monoclonal antibody) for epistaxis has been shown.
However, the efficacy of intranasal bevacizumab has yet to be evaluated. Objective To
evaluate the efficacy of 3 different doses of bevacizumab administered as a nasal spray in a
repeated manner for the duration of nosebleeds in patients with HHT. Design, Setting, and …
hemorrhagic telangiectasia (HHT). The efficacy of intravenous bevacizumab (an anti–
vascular endothelial growth factor monoclonal antibody) for epistaxis has been shown.
However, the efficacy of intranasal bevacizumab has yet to be evaluated. Objective To
evaluate the efficacy of 3 different doses of bevacizumab administered as a nasal spray in a
repeated manner for the duration of nosebleeds in patients with HHT. Design, Setting, and …